NCT05371925View on ClinicalTrials.gov

Endothelial Protection in Post COVID-19 Patients With Sulodexide

PHASE3CompletedINTERVENTIONAL

Enrollment

206

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

February 7, 2024

Study Completion Date

April 19, 2024

Conditions

Post COVID-19Endothelial DysfunctionThrombosis

Interventions

DRUG

Sulodexide

one 250LRU sulodexide capsule twice a day for 8 weeks

Trial Locations (1)

83448

Centro Medico del Noroeste, San Luis Río Colorado

Sponsors

Collaborators (1)

Alfasigma S.p.A.

All Listed Sponsors

collaborator

Alfasigma S.p.A.

INDUSTRY

lead

Centro Medico del Noroeste

OTHER

NCT05371925 - Endothelial Protection in Post COVID-19 Patients With Sulodexide | Biotech Hunter | Biotech Hunter